课题基金 / 基金详情

MTDH-RXR/PPARα-脂肪酸β氧化障碍通路介导糖尿病肾脏病肾小管上皮细胞脂毒性的机制研究

批准号:
82100750
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
刘文婷
依托单位:
学科分类:
继发性肾脏疾病
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
刘文婷

项目摘要

结项摘要

相似基金

相关文献

中文摘要
肾小管上皮细胞(RTECs)脂肪酸β氧化障碍导致脂毒性是糖尿病肾脏病(DKD)发生发展的关键因素,但发生机制未明。我们前期报道:MTDH可诱导DKD足细胞凋亡、促进RTECs炎症反应及间质纤维化,但这些病理作用是否由脂毒性介导尚不清楚。我们近期预实验结果提示:MTDH参与RTECs脂质沉积及脂毒性损伤过程,可能与MTDH的“LXXLL”基序结构竞争性抑制异二聚体RXR/PPARα对辅激活因子的募集,阻碍PPARα对脂肪酸β氧化相关酶及蛋白的转录作用有关。据此,我们提出:MTDH通过调控RXR/PPARα-脂肪酸β氧化障碍通路介导DKD中RTECs脂毒性。本项目拟利用基因打靶、超声微泡基因转导、染色质免疫沉淀等技术,以MTDH对PPARα活性调控为切入点,从体内、外体深入探讨MTDH抑制脂肪酸β氧化介导DKD肾小管脂毒性的分子机制,对发现DKD新发病机制及治疗靶点具有重要意义。
英文摘要
Renal tubular epithelial cells (RTECs) lipotoxicity due to fatty acid β-oxidation dysfunction is one of the most important mechanisms of diabetic kidney disease (DKD). However, the underling mechanism remains unclear. Previously, we reported that MTDH induced podocyte apoptosis in DKD as well as promoted RTECs inflammation and interstitial fibrosis. However, it is unclear that whether these pathological effects of MTDH are related to lipotoxicity. Recently, we found that MTDH involved in RTECs lipid deposition and lipotoxicity, which may result from the inhibition of coactivator recruit to the heterodimer of RXR/PPARα by the LXXLL motif of MTDH and thus prevents transcription of genes related in fatty acid β oxidation. We hypothesize that MTDH induces renal tubular epithelial cells lipotoxicity via regulating RXR/PPARα-mediated fatty acid oxidation dysfunction in diabetic kidney disease. In this study, we will take the regulation of PPARα activity by MTDH as a breakthrough point and clarify the molecular mechanism of MTDH induced RTECs lipotoxicity in DKD in vitro and in vivo, using technologies such as gene targeting, ultrasound microbubbles mediated gene transduction, chromatin immunoprecipitation. This study is of great significance for the discovering the new pathogenesis and looking for the potential therapeutic targets of DKD.
糖尿病肾脏病(DKD)发病率逐年升高、临床疗效差、发病机制未明。肾小管上皮细胞能量需求高,以脂肪酸为主要能量底物,易受脂肪酸代谢的影响。研究发现,脂肪酸β氧化障碍诱导的肾小管上皮细胞脂毒性是DKD发生发展的关键。然而,目前DKD肾脏脂肪酸β氧化障碍的分子机制知之甚少。本项目按书申报计划,利用基因打靶、肾实质肾盂注射腺相关病毒、Seahorse XF能量代谢检测、荧光素酶报告基因等技术,从体内外两层面深入探讨MTDH通过调控pparα的转录,抑制脂肪酸β氧化,促进DKD肾脏脂毒性发生发展的分子机制。我们结果显示DKD及棕榈酸脂(PA)干预的肾小管上皮细胞中存在明显的脂质沉积,并伴随 MTDH表达升高。体外实验结果提示下调MTDH可抑制PA诱导的肾小管上皮细胞脂毒性损伤包括抑制细胞内脂质沉积、细胞凋亡、氧化应激、线粒体损伤、炎症及纤维化反应等;而体外过表达MTDH则加重肾小管上皮细胞的脂毒性损伤。此外,我们研究结果表明MTDH通过抑制肾小管上皮细胞脂肪酸β氧化诱导细胞脂毒性。进一步研究发现MTDH通过抑制pparα从而抑制细胞脂肪酸β氧化。体内实验也发现敲除小鼠肾脏MTDH可缓解DKD小鼠肾损伤,包括缓解肾脏病理结构损伤,肾功能及尿蛋白肌酐比值的升高。体内下调小鼠肾脏组织中的MTDH可抑制DKD小鼠肾脏组织脂毒性损伤包括抑制脂质沉积、凋亡、氧化应激、炎症、纤维化及线粒体损伤。同时,体内研究结果也证实MTDH通过抑制pparα介导的脂肪酸β氧化从而抑制肾脏脂毒性的损伤。此外,在本项目研究工作开展的同时我们还发现MTDH可通过抑制线粒体基质蛋白CrAT的表达从而促进线粒体的损伤。本项目研究结果提示MTDH 通过抑制PPARα抑制脂肪酸β诱导DKD肾小管上皮细胞脂毒性,并通过抑制CrAT表达及活性促进肾小管上皮细胞线粒体损伤,明确了MTDH在DKD肾小管上皮细胞中的病理作用,揭示了DKD的新的发病机制。
国内基金
海外基金